Dhanir Tailor, Catherine C Going, Angel Resendez, Vineet Kumar, Dhanya K Nambiar, Yang Li, Arpit Dheeraj, Edward Lewis LaGory, Ali Ghoochani, Alisha M Birk, Tanya Stoyanova, Jiangbin Ye, Amato J Giaccia, Quynh-Thu Le, Rana P Singh, George W Sledge, Sharon J Pitteri, Sanjay V Malhotra
BACKGROUND: To circumvent Warburg effect, several clinical trials for different cancers are utilising a combinatorial approach using metabolic reprogramming and chemotherapeutic agents including metformin. The majority of these metabolic interventions work via indirectly activating AMP-activated protein kinase (AMPK) to alter cellular metabolism in favour of oxidative phosphorylation over aerobic glycolysis. The effect of these drugs is dependent on glycaemic and insulin conditions. Therefore, development of small molecules, which can activate AMPK, irrespective of the energy state, may be a better approach for triple-negative breast cancer (TNBC) treatment...
November 3, 2020: British Journal of Cancer